Chuck Conroy Appointed CEO of ARTMS
Summary
Prior to joining Jubilant, he was the Chief Operating Officer of PharmBlue LLC and has held leadership roles in various life sciences companies including Express Scripts, United BioSource Corporation, Covidien and Eli Lilly. “I am excited to embark on this new journey as CEO of ARTMS, leading an exceptional organization, and expanding the commercialization of its innovative technology for the production of critical medical isotopes”, said Mr. Conroy. Chuck is a remarkable leader with an impressive track record of building marketing and sales strategies and comes with a wealth of experience scaling life sciences companies” said Steven Foster, Chairman of the Board of ARTMS. Having already proven the concept and clinical application for routine and high-yield production of technetium-99m, ARTMS continues to drive a paradigm shift from the current supply chain model and is moving into advanced commercialization of cyclotron-produced gallium-68, a much sought after and valuable isotope for medical imaging in prostate and neuroendocrine tumours. ARTMS holds the exclusive global commercialization rights to award-winning and proprietary Canadian inventions which address these challenges, and which offer the prospect of revolutionizing the nuclear medicine industry.